BRONCUS-B

2216
0.5400.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:00

Overview

BRONCUS-B (2216)

Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China a...

Open
0.540
High
0.540
Low
0.540
Prev. Close
0.540
Volume
0
Turnover
0
Avg Price
--
Bid/Ask Ratio
90.48%
Amplitude
0.00%
52wk High
2.750
Volume Ratio
0.00
Turnover Ratio
--
52wk Low
0.525
HK Mkt Cap
284.62M
Market CapHKD
284.62M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.271
EPSDynamic
-0.242
EPSStatic
--
BVPS
2.13
P/B
0.25
HK Shares
527.08M
Dividend YieldTTM
--
DividendTTM
--
Shares
527.08M
Min lot size
500
Currency
HKD

BRONCUS-B Analyst Rating

View more

Forecast & Rating

Apr 1, 2025
Price forecast
HK$1.53183.87%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Broncus Holding (2216.HK) staged a recovery today, opening lower and oscillating before hitting an intraday low of HKD 0.65 in the morning session, then rallying to an intraday high of HKD 0.75 in the afternoon, closing at HKD 0.71, up 1.4% from the previous close of HKD 0.70. However, turnover was thin at only 881,000 shares, with a turnover rate of 0.17%. The move was driven by recent commercialization progress: its core BroncAblate lung radiofrequency ablation system (host and catheter) received China market approvals, and the LungPro imaging software was also cleared for sale, boosting sentiment around product monetization. Nonetheless, fundamentals remain under pressure, with Q4 2025 net loss of approximately HKD 39.22 million, widening 37.3% YoY, and EPS of -HKD 0.0807, while revenue was negative, indicating ongoing cash burn. The stock at HKD 0.71 is down 69.9% YTD and 80.9% from its 52-week high of HKD 3.72, while trading below the 60-day MA (HKD 0.989), reflecting a deeply discounted position.

News